The tariff classification of BHV-1300 and BHV-1310 from China
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the subject merchandise will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free.
Ruling text
In your letter dated June 24, 2025, you requested a tariff classification ruling on BHV-1300 and BHV-1310. This ruling request was submitted by Kirti Jadeja, Global Trade Advisory, Deloitte Tax LLP. BHV-1300 IgG is a bispecific extracellular IgG degrader currently being tested for its efficacy in the treatment of Graves’ Disease. It has an innovative mechanism for degrading and depleting pathogenic IgG in chronic and acute conditions rather than inhibition.
In your letter, you indicated the BHV-1300 will be imported for investigational research and drug development purposes to conduct Phase 1 through Phase 3 clinical trials. The BHV-1300 will be imported as the BHV-1300 drug product and BHV-1300 Active Pharmaceutical Ingredient (API). Biohaven Pharmaceuticals, Inc. (“Biohaven”) has an approved IND from the FDA for BHV-1300 to support the execution of early stage clinical trials for drug development.
The BHV-1300 drug product will be used in Phase 1 clinical trial through Phase 3 clinical trial studies to test for efficacy in treating Graves’ Disease, and other IgG mediated diseases. The BHV-1300 API will be formulated into the drug product for testing or for use in toxicology studies to evaluate safety and efficacy in disease treatment in living organisms.
BHV-1310 IgG is also a targeted extracellular protein degrader being tested against multiple autoimmune indications and, in particular, Myasthenia Gravis, or Graves’ Disease. These are bispecific molecules that target pathologic circulating proteins and direct them to the liver (or other organ systems) for degradation by the endosomal/lysosomal pathway.
In your letter, you indicated the BHV-1310 will be imported for investigational research and drug development purposes to conduct Phase 1 clinical trials and toxicology studies to evaluate the safety and efficacy in disease treatments. Biohaven has an approved IND from the FDA for BHV-1310 to support the commencement of clinical trials. The BHV-1310 will be imported as the BHV-1310 drug product and BHV-1310 API.
The BHV-1310 drug product will be used to conduct Phase 1 clinical trials, and the BHV-1310 API will be used in toxicology studies to evaluate the safety and efficacy in disease treatment in living organisms. The BHV-1300 and BHV-1310 will be imported in four different forms as follows: 1. API in powder form. 2. Sterile drug product solution in glass vials. 3. Single use Prefilled Syringe (“PFS”) assembled into an auto-injector device (includes the drug product solution). 4.
PFS without the auto-injector device (includes the drug product solution).
You inquired about whether the imported BHV-1300 and BHV-1310 qualifies for duty free treatment as a prototype under subheading 9817.85.01, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” You indicated that Biohaven will import the BHV-1300 and BHV-1310 for further drug development in limited non-commercial quantities in accordance with industry practice solely to conduct FDA clinical trials and toxicology studies.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N350567).